Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Erlotinib vs Erlotinib in Chinese EGFR-mutated NSCLC (Artemis)
NCT02759614Phase 3Completed
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Apr 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Apr 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02759614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759614.